Document Detail

Antimalarial drugs, pregnancy and lactation.
MedLine Citation:
PMID:  8485567     Owner:  NLM     Status:  MEDLINE    
Disease activity has been demonstrated to be one of the major factors contributing to fetal loss in SLE patients, and discontinuation of antimalarial therapy can precipitate a flare of disease. It is therefore important to determine whether it is safe to continue antimalarial therapy throughout pregnancy. We have previously stated that we consider lupus patients and their fetuses to be at risk for disaster if antimalarial therapy is discontinued during pregnancy, and it has been our experience that lupus patients can produce normal offspring even if they are taking daily chloroquine or hydroxychloroquine. Several other reports now support our findings that it is probably safe to continue antimalarial therapy during pregnancy, although there are no large studies published. Data on the secretion of hydroxychloroquine in the breast milk of patients on steady-state hydroxychloroquine therapy are minimal, and further studies are required to determine whether these women can safely nurse their infants while taking hydroxychloroquine daily.
A L Parke
Related Documents :
2248137 - Detection of truncated dystrophin in fetal dmd myotubes.
24783017 - Side effects of anti-thyroid drugs and their impact on the choice of treatment for thyr...
10968047 - The occurrence of autoantibodies in sera of healthy pregnant women.
2691157 - Pregnancy in systemic lupus erythematosus.
18442997 - Factors affecting low birthweight after assisted reproduction technology: difference be...
18366447 - Steady-state nevirapine plasma concentrations are influenced by pregnancy.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Lupus     Volume:  2 Suppl 1     ISSN:  0961-2033     ISO Abbreviation:  Lupus     Publication Date:  1993 Feb 
Date Detail:
Created Date:  1993-06-04     Completed Date:  1993-06-04     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  9204265     Medline TA:  Lupus     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  S21-3     Citation Subset:  IM    
University of Connecticut Health Center, Department of Medicine, Farmington, CT 06030-1310.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antimalarials / adverse effects,  pharmacokinetics,  therapeutic use*
Lupus Erythematosus, Systemic / drug therapy*
Milk, Human / metabolism
Pregnancy Complications / drug therapy*
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ophthalmologic safety profile of antimalarial drugs.
Next Document:  The efficacy of antimalarials in systemic lupus erythematosus.